BIOCHEMICAL PHARMACOLOGY OF ANTITUMOR DRUGS

Project: Research project

Project Details

Description

The aims of this proposal are to 1) further analyze the mechanism of action
of bleomycin in vitro, (2) restrict the cytotoxicity of bleomycin to tumor
cells, 3) understand the basis for resistance to the growth inhibitory
properties of bleomycin and 4) study the degradation of DNA by VP-16-213.

In vitro experiments with bleomycin will 1) define the role of metals other
than iron and of phosphate anion in the action of the drug; 2) determine
the early lesions in DNA and the final products of DNA degradation; 3)
reveal the origin of the oxygen present in the products of DNA degradation;
and 4) search for a covalent association with DNA.

Cellular studies with bloemycin will examine ways in which the specificity
of the drug for tumor cells can be enhanced. Experiments will focus on the
role of oxygen in drug activity and on the modification of drug uptake.
Covalent conjugates of bloemycin with bovine serum albumin, IgG and
monoclonal antibodies will be prepared and their cytotoxic activity
determined and compared to that of free drug.

Bleomycin-resistant cells will be evaluated for the stability of the
resistant phenotype, cross-resistance to other drugs, alterations in drug
uptake, changes in membrane components and karyotype. Several new proteins
induced in the drug-resistant cells will be purified, characterized in
terms of localization and biosynthesis and antibodies will be developed
against them.

An in vitro assay for the degradation of DNA by VP-16-213 will be
developed. The effects of VP-16-213 on DNA synthesis and degradation of
adenovirus and SV40 DNA in infected cells will be determined.
Singe-stranded breaks in adenovirus DNA will be characterized after
infection of HeLa cells.
StatusFinished
Effective start/end date1/1/901/1/90

Funding

  • National Cancer Institute

ASJC

  • Biochemistry
  • Pharmacology

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.